{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:07:26Z","timestamp":1779790046365,"version":"3.53.1"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with proven efficacy in EGFR-mutant non\u2013small cell lung cancer (NSCLC), including patients with central nervous system (CNS) disease. However, pharmacokinetic (PK) studies demonstrate low CNS penetration (CSF:plasma 0.8%\u201322%), largely due to ABCB1\/ABCG2 efflux. OB-001, a KinetiSol amorphous solid dispersion formulation of elacridar, was developed to overcome the poor bioavailability of crystalline elacridar and evaluated as a strategy to enhance osimertinib brain delivery. In CD-1 mice, we compared the oral bioavailability of OB-001 (10, 30, 100 mg\/kg) with crystalline elacridar (100 mg\/kg) and assessed osimertinib (50 mg\/kg orally) brain distribution after pretreatment with OB-001 (10 or 50 mg\/kg) or crystalline elacridar (100 mg\/kg). Plasma and perfused brain PK parameters were derived by noncompartmental analysis. AUClast values were compared using Bailer randomization test. OB-001 achieved greater systemic elacridar exposure than the crystalline methylcellulose suspension (P &amp;lt; 0.001). In vehicle-pretreated mice, osimertinib produced a brain:plasma AUC ratio of 7.1. OB-001 pretreatment increased brain AUClast 4-fold (10 mg\/kg; P &amp;lt; 0.001) and 9.3-fold (50 mg\/kg; P &amp;lt; 0.001) with minimal plasma change (1.1\u20131.4-fold). Crystalline elacridar at 100 mg\/kg increased brain AUClast 5-fold (P &amp;lt; 0.001). Thus, OB-001 at 10 mg\/kg achieved comparable brain enhancement with 10-fold higher dose of crystalline elacridar, whereas OB-001 at 50 mg\/kg exceeded it. Translational benchmarking against in vitro potency suggested that raising estimated Kp,uu from \u223c0.15 to \u223c0.60 could improve efficacy. OB-001 selectively boosts osimertinib brain exposure while sparing systemic PK. These preclinical data support further evaluation of OB-001 as a strategy to enhance the CNS efficacy of osimertinib in EGFR-mutant NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Blood\u2013brain barrier (BBB) efflux limits osimertinib brain exposure. Oral OB-001 pretreatment markedly increases brain concentrations with minimal plasma impact, supporting BBB transporter inhibition as a strategy to enhance CNS drug delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0553","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:46:42Z","timestamp":1778186802000},"page":"1213-1219","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OB-001 Enhances Osimertinib Brain Penetration: Preclinical Pharmacokinetics and Translational Rationale for EGFR-Mutant NSCLC with CNS Disease"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-1903","authenticated-orcid":false,"given":"Hitesh B.","family":"Mistry","sequence":"first","affiliation":[{"name":"OncoBayesAlpha Ltd., London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4058-467X","authenticated-orcid":false,"given":"Jim","family":"Millen","sequence":"additional","affiliation":[{"name":"OncoBayesAlpha Ltd., London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4232-7382","authenticated-orcid":false,"given":"Josh","family":"Fleet","sequence":"additional","affiliation":[{"name":"OncoBayesAlpha Ltd., London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6793-3234","authenticated-orcid":false,"given":"Mark","family":"Brimble","sequence":"additional","affiliation":[{"name":"OncoBayesAlpha Ltd., London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026052606013436500_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"2026052606013436500_bib2","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J Med Chem"},{"key":"2026052606013436500_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026052606013436500_bib4","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026052606013436500_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026052606013436500_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation\u2013positive non\u2013small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052606013436500_bib7","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026052606013436500_bib8","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib in radiotherapy-na\u00efve patients with EGFR mutation-positive non\u2013small cell lung cancer and brain metastases: the OCEAN study (LOGIK 1603\/WJOG 9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026052606013436500_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0271678X19843776","article-title":"A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib \u2013 a drug intended for treatment of brain metastases in non-small cell lung cancer","volume":"40","author":"Varrone","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026052606013436500_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cts.13500","article-title":"Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study","volume":"16","author":"Ekman","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026052606013436500_bib11","doi-asserted-by":"crossref","first-page":"104297","DOI":"10.1016\/j.phrs.2019.104297","article-title":"Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)","volume":"146","author":"van Hoppe","year":"2019","journal-title":"Pharmacol Res"},{"key":"2026052606013436500_bib12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1208\/s12249-018-1007-2","article-title":"Expanding the application and formulation space of amorphous solid dispersions with KinetiSol\u00ae: a review","volume":"19","author":"Ellenberger","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"2026052606013436500_bib13","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1208\/s12249-018-0988-1","article-title":"Improved vemurafenib dissolution and pharmacokinetics as an amorphous solid dispersion produced by KinetiSol\u00ae processing","volume":"19","author":"Ellenberger","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"2026052606013436500_bib14","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.molpharmaceut.0c00108","article-title":"In vitro and in vivo behaviors of KinetiSol and spray-dried amorphous solid dispersions of a weakly basic drug and ionic polymer","volume":"17","author":"Jermain","year":"2020","journal-title":"Mol Pharm"},{"key":"2026052606013436500_bib15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/jps.21893","article-title":"Fusion processing of itraconazole solid dispersions by KinetiSol Dispersing: a comparative study to hot melt extrusion","volume":"99","author":"DiNunzio","year":"2010","journal-title":"J Pharm Sci"},{"key":"2026052606013436500_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ctrv.2016.09.012","article-title":"Inventory of oral anticancer agents: pharmaceutical formulation aspects with focus on the solid dispersion technique","volume":"50","author":"Sawicki","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2026052606013436500_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/(SICI)1099-1263(199609)16:5<391::AID-JAT363>3.0.CO;2-C","article-title":"Randomization tests for assessing the equality of area under curves for studies using destructive sampling","volume":"16","author":"Bailer","year":"1996","journal-title":"J Appl Toxicol"},{"key":"2026052606013436500_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.104.068288","article-title":"Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey","volume":"310","author":"Ward","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2026052606013436500_bib19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1124\/dmd.112.045930","article-title":"Brain distribution and bioavailability of elacridar after different routes of administration in the mouse","volume":"40","author":"Sane","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"2026052606013436500_bib20","first-page":"2849","article-title":"Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein","volume":"9","author":"Kemper","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026052606013436500_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"2026052606013436500_bib22","doi-asserted-by":"crossref","first-page":"1234262","DOI":"10.3389\/fphar.2023.1234262","article-title":"Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026052606013436500_bib23","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026052606013436500_bib24","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026052606013436500_bib25","first-page":"1529","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0553\/3793295\/crc-25-0553.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1213\/3797051\/crc-25-0553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1213\/3797051\/crc-25-0553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:01:41Z","timestamp":1779789701000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1213\/785405\/OB-001-Enhances-Osimertinib-Brain-Penetration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0553","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}